Joint application:
- with methotrexate at a dose of 15 mg per week or more is a contraindication: the hemolytic cytotoxicity of methotrexate is increased (decreased renal clearance of methotrexate and methotrexate is replaced by salicylates in association with blood plasma proteins);
- with anticoagulants, for example, heparin: increased risk of bleeding due to a violation of platelet function, damage to the mucous membrane of the gastrointestinal tract, the displacement of anticoagulants (indirect) from the connection with plasma proteins;
- with other non-steroidal anti-inflammatory drugs: as a result of synergistic interaction, the risk of ulcers and bleeding from the stomach and duodenum increases;
- with uricosuric medicines, for example, benzbromarone: reduces the uricosuric effect;
- with digoxin: the concentration of digoxin is increased due to decreased renal excretion;
- with hypoglycemic drugs: hypoglycemic effect of hypoglycemic drugs increases due to hypoglycemic effect of acetylsalicylic acid;
- with preparations of the thrombolytics group: the fibrinolytic effect of the latter increases and the risk of bleeding increases;
- with glucocorticosteroids, excluding hydrocortisone, used as a substitute therapy for Addison's disease: with the use of glucocorticosteroids, the concentration of salicylates in the blood decreases by increasing the excretion of the latter;
- with inhibitors of the angiotensin-converting enzyme: glomerular filtration is reduced by inhibiting the synthesis of prostaglandins and, as a consequence, the antihypertensive effect is reduced;
- with valproic acid: the toxicity of valproic acid increases;
- with glucocorticosteroids, ethanol (alcoholic beverages) and ethanol containing medicines: the risk of damaging effects on the mucous membrane of the gastrointestinal tract increases, the risk of developing gastrointestinal bleeding increases;
- intensifies the effects of narcotic analgesics, indirect anticoagulants and antiaggregants, sulfonamides (including co-trimoxazole - increases their activity and toxicity), triiodothyronine (increases activity and increases the risk of side effects of the latter);
- reduces the effect of antihypertensive drugs, diuretics (spironolactone, furosemide);
- increases the concentration of barbiturates, lithium salts in plasma;
- antacids containing magnesium and / or aluminum slow down and worsen the absorption of acetylsalicylic acid;
- Myelotoxic drugs increase the manifestation of hematotoxicity of the drug.